stoxline Quote Chart Rank Option Currency Glossary
BioCryst Pharmaceuticals, Inc. (BCRX)
6.28  -0.19 (-2.94%)    05-17 16:00
Open: 6.43
High: 6.5582
Volume: 4,165,735
Pre. Close: 6.47
Low: 6.22
Market Cap: 1,296(M)
Technical analysis
2024-05-17 4:44:13 PM
Short term     
Mid term     
Targets 6-month :  7.69 1-year :  8.99
Resists First :  6.59 Second :  7.69
Pivot price 5.21
Supports First :  5 Second :  4.03
MAs MA(5) :  6.01 MA(20) :  4.98
MA(100) :  5.37 MA(250) :  6.2
MACD MACD :  0.3 Signal :  0.1
%K %D K(14,3) :  91.5 D(3) :  86.7
RSI RSI(14): 69
52-week High :  8.96 Low :  4.03
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BCRX ] has closed below upper band by 13.4%. Bollinger Bands are 130.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.57 - 6.6 6.6 - 6.63
Low: 6.14 - 6.18 6.18 - 6.21
Close: 6.22 - 6.28 6.28 - 6.34
Company Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Headline News

Thu, 16 May 2024
New York State Common Retirement Fund Sells 17821 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

Wed, 15 May 2024
Insider Buying: Chief R&D Officer Helen Thackray Acquires 30000 Shares of BioCryst ... - Yahoo Finance

Wed, 15 May 2024
Director Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX) - Yahoo Finance

Wed, 15 May 2024
Insider Buying: Charles Gayer Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - Yahoo Finance

Wed, 15 May 2024
Insider Buying: CFO Anthony Doyle Acquires Shares of BioCryst Pharmaceuticals Inc (BCRX) - Yahoo Finance

Wed, 15 May 2024
BioCryst stock spikes on insider purchases (NASDAQ:BCRX) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 206 (M)
Shares Float 191 (M)
Held by Insiders 1 (%)
Held by Institutions 88.5 (%)
Shares Short 33,640 (K)
Shares Short P.Month 32,250 (K)
Stock Financials
EPS -1.08
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.31
Profit Margin -58.7 %
Operating Margin -15.7 %
Return on Assets (ttm) -10.9 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 34.9 %
Gross Profit (p.s.) 0
Sales Per Share 1.72
EBITDA (p.s.) -0.4
Qtrly Earnings Growth 0 %
Operating Cash Flow -101 (M)
Levered Free Cash Flow -72 (M)
Stock Valuations
PE Ratio -5.87
PEG Ratio -0.2
Price to Book value -2.72
Price to Sales 3.64
Price to Cash Flow -12.8
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android